Udaya Rangaswamy | Director of Translational Biology
Rondo Therapeutics
Udaya Rangaswamy is Director of translational biology at Rondo therapeutics, a start-up focused on novel multi-specific engagers for solid tumors. Prior to Rondo, Udaya was a Principal Scientist at Amgen following Amgen’s acquisition of Teneobio in 2021. Between both Amgen and Teneobio, Udaya has supported development of CD3-based bispecific antibodies from lead optimization through first-in-human studies, including three programs currently active in the clinic. Prior to Teneobio, Udaya was a post-doc at MedImmune/Astrazeneca working on an oncolytic virus platform. Udaya received her PhD in microbiology and molecular genetics from Emory University and her thesis work identified novel signaling pathways driving the pathogenesis of an oncogenic viral protein.
Appearances:
Festival of Biologics Day 1 @ 15:40
CD28-based costimulatory bispecific antibody platform for the treatment of solid tumors
CD3-based T cell engagers have had limited success in treatment of solid tumors, due to on-target off-tumor toxicity concerns or due to a suppressive tumor microenvironment. Rondo’s bispecific platform is designed to specifically engage the costimulatory receptor, CD28, in the tumor microenvironment to enable a robust T cell response only in the presence of signal 1 from endogenous pMHC-TCR signals or CD3 based bispecifics. We present preclinical data on our lead candidate RNDO-564, a CD28 and Nectin-4 targeted bispecific antibody for the treatment of metastatic bladder cancer.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events